The latest market report published by Credence Research, Inc. “Hemostasis/Coagulation Analyzers Market – Growth, Future Prospects, Competitive Analysis, 2018 – 2026,” the global hemostasis/coagulation analyzers market was valued at US$ 3,650.1 Mn in 2017 and expected to reach US$ 9,548.0 Mn by 2026, expanding at a CAGR of 9.9% from 2018 to 2026.
[Note: Our Free Complimentary Sample Report Accommodate a Brief Introduction To The Synopsis, TOC, List of Tables and Figures, Competitive Landscape and Geographic Segmentation, Innovation and Future Developments Based on Research Methodology are also Included]
Increasing occurrence of blood disorders is mainly due to the development of the market for haemostasis analyzers. Hemostasis/ coagulation tests are usually conducted for three reasons: diagnosis of diseases, screening for coagulation disorders and control of therapy. hemostasis tests are performed on almost every hospitalized patient, as the most reliable predictor of bleeding risk in any procedure is the history of bleeding. hemostasis analyzers help treat patients with bleeding disorders and abnormal blood clotting. Perpetual advances in technology and miniaturization have led to the commercialization of many new devices that have a quick turnaround time and can also be used in care settings. In addition, rising knowledge and demand for technologically advanced medical treatments, government support and the growing acceptance of laboratory automation stimulate demand for novel coagulation analyzers.
The global market for haemostasis / coagulation analyzers is segmented into test methods, product types and end users. Routine coagulation tests hold the largest share of the global market among the test forms. A large number of these tests, which are performed for almost all surgical procedures and treatments, mainly contribute to the dominance of this segment. Growing the adoption of specific tests, such as VWF assays and thrombophilia tests, with a view to increasing awareness and prevalence of coagulation disorders, would promote faster growth in the segment of diagnostic hemostasis assays. Today, between instruments (analyzers) and consumables, the former segment has a greater share of revenue globally. Higher cost and steadily increasing purchases of these systems, both in laboratory and point-of-care settings, are attributed to the importance of the device segment.
Based on end users, the global market for haemostasis / coagulation analyzers is being studied in hospitals and clinics, diagnostic laboratories and research institutions. Among these, the analytical laboratory segment dominated the global market. This segment is mainly driven by a greater preference for analysis of samples in specialized laboratories. The adoption of hemostasis analyzers in research institutions is high due to an increase in the number of clinical trials in the field of medication and novel diagnostic solutions.
In 2017, North America dominated the global market for haemostasis analyzers in terms of revenue, due to the existence of established healthcare infrastructure, a multitude of R&D programs, a high number of organ transplants and general surgeries in the area, and so on. On the other hand, Asia Pacific will see the fastest growth on the global front. Growing awareness of haemostasis, growing prevalence of both genetic and lifestyle disorders and rising spending on health care are key drivers of this regional market.
The competitive front of the haemostasis industry is strong and is marked by the involvement of a variety of international players. Major market players have stepped up their R&D efforts to develop technologically advanced and more reliable analyzers. We are also pursuing expansion steps to reach the untapped markets of Asia Pacific and Middle East and Africa.
Some of the key players engaged in the global hemostasis/coagulation analyzers market are Alere Inc. (Abbott Laboratories, Inc.), F-Hoffmann La Roche, Sysmex Corporation, Beckman Coulter, Inc. (Danaher), Nihon Kohden Corporation, Thermo Fisher Scientific Inc., Siemens Healthcare (Siemens AG), International Technidyne Corporation (Werfen), and Beckman Coulter Inc.
Key Market Movements:
Growing incidence of hematological diseases and increasing preference for coagulation tests in all surgical procedures
The rapid evolution of healthcare infrastructure in untapped markets of Asia Pacific
Growing preference for novel compact and automatic analyzers that can be used in point of care settings
Growing efforts to commercialize novel drugs for the treatment of coagulation disorders
Rapid penetration of major market players in the emerging regions and Asia Pacific, parts of Latin America and Middle East & Africa